Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | ALDH2 | P05091 | 2/20 | 0.32 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.32 |
| ▸ | PDE5A | O76074 | 1/20 | 0.32 |
| ▸ | PDE9A | O76083 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL4469315 | 0.99 | ALDH1A1 (0.32) | ALDH1A1ALDH2ALDH3A1PDE5APDE9A | |
| Fumaric Acid SCHEMBL4469314 | 0.94 | ALDH1A1 (0.30) | ALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL4185595 | 0.93 | ALDH1A1 (0.35) | ALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL4181329 | 0.93 | ALDH1A1 (0.35) | ALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL1385654 | 0.93 | ALDH1A1 (0.35) | ALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL4469323 | 0.88 | — | — | |
| SCHEMBL4463077 | 0.86 | ALDH1A1 (0.37) | ALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL4473322 | 0.86 | ALDH1A1 (0.37) | ALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL4463085 | 0.86 | ALDH1A1 (0.37) | ALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL4240395 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283374-B2 | Process for preparing (3-oxo-2,3-dihydro-1H-isoindol-1-yl) acetylguanidine derivatives | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-10-09 | — | — | US | claimed |
| US-20090203761-A1 | PROCESS FOR PREPARING (3-OXO-2,3-DIHYDRO-1H-ISOINDOL-1-YL) ACETYLGUANIDINE DERIVATIVES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-08-13 | — | — | US | claimed |
| US-8283374-B2 | Process for preparing (3-oxo-2,3-dihydro-1H-isoindol-1-yl) acetylguanidine derivatives | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-10-09 | — | — | US | disclosed |
| US-20090203761-A1 | PROCESS FOR PREPARING (3-OXO-2,3-DIHYDRO-1H-ISOINDOL-1-YL) ACETYLGUANIDINE DERIVATIVES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-08-13 | — | — | US | disclosed |
| US-7531569-B2 | Process for preparing (3-oxo-2,3-dihydro-1H-isoindol-1-yl) acetylguanidine derivatives | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-05-12 | — | — | US | disclosed |
| US-20050124681-A1 | Process for preparing (3-oxo-2,3-dihydro-1H-isoindol-1-yl) acetylguanidine derivatives | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124681-A1 | Process for preparing (3-oxo-2,3-dihydro-1H-isoindol-1-yl) acetylguanidine derivatives | OGG1, HBG2, OGDH | ALDH1A1 188/4885ALDH2 823/4885ALDH3A1 268/4885 |
| US-20090203761-A1 | PROCESS FOR PREPARING (3-OXO-2,3-DIHYDRO-1H-ISOINDOL-1-YL) ACETYLGUANIDINE DERIVATIVES | OGT, B3GNT2, UGT1A9 | ALDH1A1 13/4885ALDH2 182/4885ALDH3A1 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.